Prasugrel Krka
Antiplatelet agent for prevention of blood clots after heart attack or stent placement
Prasugrel Krka is an antiplatelet medicine containing the active substance prasugrel. It is prescribed to prevent dangerous blood clots (thrombosis) in patients who have experienced a heart attack or unstable angina and have undergone percutaneous coronary intervention (PCI) such as stent placement. Prasugrel Krka is always taken together with aspirin as part of dual antiplatelet therapy. This guide covers uses, dosage, side effects, interactions, and important safety information based on international cardiology guidelines.
Quick Facts
Key Takeaways
- Prasugrel Krka prevents blood clots by irreversibly blocking the P2Y12 receptor on platelets, reducing the risk of heart attack, stroke, and cardiovascular death after acute coronary syndrome (ACS) treated with PCI.
- The standard maintenance dose is 10 mg once daily, with a reduced 5 mg dose for patients aged 75 or older or weighing less than 60 kg. Treatment begins with a one-time loading dose of 60 mg.
- Prasugrel must not be used in patients with a history of stroke or transient ischaemic attack (TIA), active bleeding, or severe liver disease.
- Bleeding is the most common side effect. Report any unexplained or prolonged bleeding to your doctor immediately.
- Always take prasugrel together with aspirin as prescribed. Do not stop treatment without consulting your doctor, as premature discontinuation increases the risk of stent thrombosis and heart attack.
What Is Prasugrel Krka and What Is It Used For?
Prasugrel Krka contains the active substance prasugrel, which belongs to a group of medicines called antiplatelet agents (specifically, thienopyridine P2Y12 receptor antagonists). Platelets are very small cells in the blood that play a crucial role in forming blood clots. When a blood vessel is damaged, platelets clump together to form a clot that stops bleeding. While this process is essential for wound healing, blood clots that form inside narrowed or atherosclerotic arteries can be extremely dangerous.
When a blood clot forms inside a coronary artery (the blood vessels that supply the heart), it can completely block blood flow and cause a myocardial infarction (heart attack). Blood clots in arteries can also cause unstable angina (severe chest pain due to reduced blood flow to the heart) or, if they travel to the brain, a stroke. These cardiovascular events can be life-threatening and require immediate medical intervention.
Prasugrel Krka works by irreversibly blocking the P2Y12 receptor on the surface of platelets. This receptor normally responds to adenosine diphosphate (ADP), a chemical signal that activates platelets and promotes clot formation. By blocking this receptor, prasugrel prevents platelets from clumping together and significantly reduces the risk of forming dangerous blood clots within the arteries.
Prasugrel Krka is prescribed to patients who have already experienced a heart attack or unstable angina and have been treated with percutaneous coronary intervention (PCI), a procedure that opens blocked coronary arteries. During PCI, one or more coronary stents (small mesh tubes) may be placed inside the artery to keep it open. Patients who receive stents are at particular risk of blood clots forming on the stent surface (stent thrombosis), which can cause another heart attack. Prasugrel Krka, taken together with aspirin (acetylsalicylic acid), forms dual antiplatelet therapy (DAPT) that effectively prevents this complication.
The landmark TRITON-TIMI 38 trial, published in the New England Journal of Medicine, demonstrated that prasugrel was superior to clopidogrel in reducing the combined endpoint of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in patients with acute coronary syndromes undergoing PCI. This established prasugrel as a preferred P2Y12 inhibitor in this clinical setting, as recommended by both the European Society of Cardiology (ESC) and the American Heart Association (AHA).
What Should You Know Before Taking Prasugrel Krka?
Contraindications
There are several important situations in which Prasugrel Krka must not be used. Understanding these contraindications is essential for safe treatment. Do not take Prasugrel Krka if:
- You are allergic to prasugrel or any of the other ingredients in this medicine. An allergic reaction may manifest as skin rash, itching, swelling of the face or lips, or shortness of breath. If you experience any of these symptoms, contact your doctor immediately.
- You have active pathological bleeding, such as bleeding from a stomach ulcer or intestinal bleeding. Prasugrel inhibits the blood's ability to clot, which can worsen existing bleeding conditions.
- You have ever had a stroke or transient ischaemic attack (TIA). The TRITON-TIMI 38 trial identified that patients with prior cerebrovascular events had a net clinical harm from prasugrel due to an increased risk of intracranial bleeding. This is a critical contraindication that distinguishes prasugrel from other antiplatelet agents.
- You have severe hepatic (liver) impairment. Severe liver disease can affect the metabolism of prasugrel and increase bleeding risk.
Unlike clopidogrel, prasugrel is contraindicated in patients with prior cerebrovascular events. The TRITON-TIMI 38 trial showed that these patients had an increased risk of intracranial haemorrhage with prasugrel compared to clopidogrel. If you have had a stroke or TIA, your doctor will prescribe an alternative antiplatelet agent.
Warnings and Precautions
Before starting treatment with Prasugrel Krka, talk to your doctor or pharmacist about your complete medical history. It is particularly important to inform your doctor if any of the following apply to you:
Increased risk of bleeding: Certain factors may increase your risk of bleeding while taking prasugrel. Your doctor will carefully weigh the benefits of preventing blood clots against the risk of bleeding if you:
- Are 75 years of age or older. Elderly patients have a higher risk of bleeding. Your doctor should prescribe a reduced daily dose of 5 mg. The ESC guidelines recommend careful risk-benefit assessment in this age group.
- Weigh less than 60 kg. Low body weight is associated with increased drug exposure and bleeding risk. A daily dose of 5 mg is recommended for patients below this weight threshold.
- Have had a recent serious injury or have recently undergone surgery, including dental procedures.
- Have a history of gastrointestinal bleeding, such as from stomach ulcers or colon polyps.
- Have kidney disease or moderate liver problems (not classified as severe).
- Are taking certain medications that increase bleeding risk (see the drug interactions section below).
Planned surgery: If you are scheduled for any surgery, including dental procedures, within the next seven days, inform your surgeon or dentist that you are taking Prasugrel Krka. Your doctor may advise you to temporarily stop taking the medicine to reduce the risk of excessive bleeding during and after the procedure. The ESC recommends discontinuing prasugrel at least 7 days before elective surgery.
Previous allergic reactions to antiplatelet agents: If you have previously experienced allergic reactions (hypersensitivity) to clopidogrel or any other antiplatelet medicine, inform your doctor before starting Prasugrel Krka. While cross-reactivity is uncommon, your doctor should be aware of your allergy history.
Contact your doctor immediately if you develop a condition called thrombotic thrombocytopenic purpura (TTP), which may present with fever, bleeding under the skin appearing as tiny red pinpoint spots, unexplained extreme tiredness, confusion, or yellowing of the skin or eyes (jaundice). TTP is a rare but serious condition that requires immediate medical attention.
Pregnancy and Breastfeeding
If you are pregnant, breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. The safety of prasugrel during pregnancy has not been established in adequate human studies. Prasugrel should only be used during pregnancy if the potential benefit to the mother justifies the potential risk to the foetus. Discuss the risks and benefits thoroughly with your doctor.
It is not known whether prasugrel or its metabolites are excreted in human breast milk. A decision should be made whether to discontinue breastfeeding or to discontinue prasugrel therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother.
Driving and Operating Machinery
Prasugrel Krka is not expected to affect your ability to drive or operate machinery. However, if you experience dizziness or other side effects that may impair your alertness, do not drive or operate heavy machinery until these symptoms resolve.
Prasugrel Krka tablets contain lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine. This medicine also contains less than 1 mmol sodium (23 mg) per dose, meaning it is essentially sodium-free.
How Does Prasugrel Krka Interact with Other Drugs?
Drug interactions are a critical consideration when taking Prasugrel Krka. Inform your doctor or pharmacist about all medicines you are currently taking, have recently taken, or might take, including over-the-counter medicines, dietary supplements, and herbal remedies. Some medications can significantly increase your risk of bleeding or alter the effectiveness of prasugrel when taken together.
Major Interactions
The following drug interactions are considered clinically significant and require careful medical supervision or avoidance:
| Drug / Drug Class | Interaction Effect | Clinical Recommendation |
|---|---|---|
| Warfarin (oral anticoagulant) | Significantly increased bleeding risk due to dual inhibition of coagulation pathways | Avoid combination unless specifically directed by a specialist; requires close monitoring of INR |
| NSAIDs (ibuprofen, naproxen, etoricoxib) | Increased risk of gastrointestinal bleeding and overall bleeding complications | Avoid chronic NSAID use; use paracetamol (acetaminophen) for pain relief when possible |
| Clopidogrel (antiplatelet agent) | No additional benefit; increased bleeding risk from dual P2Y12 inhibition | Do not use simultaneously; prasugrel replaces clopidogrel in the treatment regimen |
| Opioids (morphine, fentanyl) | Reduced gastrointestinal absorption, delayed onset and reduced peak plasma levels of prasugrel's active metabolite | In the acute setting (e.g., during STEMI), consider alternative analgesics or monitor for adequate platelet inhibition |
| Direct oral anticoagulants (DOACs) (rivaroxaban, apixaban, dabigatran) | Markedly increased bleeding risk with triple antithrombotic therapy | Triple therapy should be limited to the shortest possible duration; specialist cardiology guidance required |
Minor Interactions
Some interactions are less clinically significant but should still be discussed with your doctor:
- Proton pump inhibitors (PPIs) such as omeprazole and pantoprazole: Unlike clopidogrel, prasugrel's activation is not significantly affected by PPIs. Co-administration is generally considered safe and may be beneficial for reducing gastrointestinal bleeding risk.
- Statins (atorvastatin, rosuvastatin): No clinically significant interaction. Statins are commonly co-prescribed with prasugrel in patients with coronary artery disease.
- ACE inhibitors and ARBs (ramipril, losartan): No significant interaction. These blood pressure medications are frequently used alongside prasugrel without dose adjustment.
- Beta-blockers (metoprolol, bisoprolol): No clinically relevant interaction. Safe to use together as part of standard post-ACS therapy.
Only take medications together with Prasugrel Krka that your doctor has approved. Even over-the-counter pain relievers and supplements may interact with antiplatelet therapy. Always carry a list of your current medications and show it to any healthcare provider before receiving new prescriptions or undergoing procedures.
What Is the Correct Dosage of Prasugrel Krka?
Always take Prasugrel Krka exactly as your doctor or pharmacist has told you. Do not change your dose or stop taking the medicine without consulting your doctor first. Prasugrel Krka is always prescribed as part of dual antiplatelet therapy (DAPT) alongside aspirin (acetylsalicylic acid).
Adults (Standard Dosing)
| Patient Group | Loading Dose | Maintenance Dose | Aspirin Dose |
|---|---|---|---|
| Standard adult (under 75 years, 60 kg or more) | 60 mg (single dose) | 10 mg once daily | 75-325 mg daily |
| Elderly (75 years or older) | 60 mg (single dose) | 5 mg once daily | 75-100 mg daily |
| Low body weight (under 60 kg) | 60 mg (single dose) | 5 mg once daily | 75-100 mg daily |
The loading dose of 60 mg is given at the time of PCI to achieve rapid and potent platelet inhibition. Your doctor will administer this initial dose in the hospital setting. After this, you will take the maintenance dose of 10 mg (or 5 mg if applicable) once daily at approximately the same time each day.
How to Take Prasugrel Krka
- Prasugrel Krka can be taken with or without food.
- Swallow the tablet whole with water. Do not break, crush, or chew the tablets.
- Take your dose at approximately the same time each day to maintain consistent platelet inhibition.
- Duration of treatment is typically 12 months, but your doctor may adjust this based on your individual risk profile.
Children and Adolescents
Prasugrel Krka should not be used in children and adolescents under 18 years of age. There are insufficient data on the safety and efficacy of prasugrel in this age group, and acute coronary syndromes requiring PCI are exceptionally rare in paediatric patients.
Elderly Patients
Patients aged 75 years or older should receive a reduced maintenance dose of 5 mg once daily due to the increased risk of bleeding in this population. The TRITON-TIMI 38 trial demonstrated that elderly patients had a higher rate of bleeding events, including fatal and intracranial bleeding, with the standard 10 mg dose. The ESC 2023 ACS guidelines recommend careful evaluation of the bleeding risk versus the thrombotic benefit in elderly patients. The loading dose remains 60 mg.
Missed Dose
If you miss your daily dose, take it as soon as you remember. If you do not remember until the following day, simply take your usual dose at your regular time. Do not take a double dose to make up for a missed dose. Missing a single dose is unlikely to cause problems, but consistently missing doses may increase your risk of blood clots. If you frequently forget your medication, consider setting a daily alarm or using a pill organiser.
Overdose
If you take more Prasugrel Krka than prescribed, or if a child accidentally ingests the medicine, contact your doctor, hospital, or poison control centre immediately. An overdose of prasugrel may lead to severe and potentially life-threatening bleeding. There is no specific antidote for prasugrel. Treatment is supportive and may include platelet transfusion. Show the healthcare provider your Prasugrel Krka packaging.
Stopping Treatment
Do not stop taking Prasugrel Krka without first discussing it with your doctor. Premature discontinuation of antiplatelet therapy, particularly within the first 12 months after stent placement, dramatically increases the risk of stent thrombosis, a potentially fatal complication. Stent thrombosis can cause a massive heart attack and has a mortality rate of up to 40%. If you need to stop prasugrel for any reason, such as planned surgery, your doctor will advise you on the safest approach, which may include bridging therapy.
It is essential to inform all healthcare providers, including dentists, that you are taking Prasugrel Krka. This information is critical for managing bleeding risk during any medical or dental procedure.
What Are the Side Effects of Prasugrel Krka?
Like all medicines, Prasugrel Krka can cause side effects, although not everybody gets them. Because prasugrel works by reducing the blood's ability to clot, bleeding is the most frequently reported side effect. Most bleeding events are mild to moderate in severity, but serious and life-threatening bleeding can occur.
- Sudden numbness or weakness in the arm, leg, or face, especially on one side of the body
- Sudden confusion, difficulty speaking, or difficulty understanding others
- Sudden difficulty walking, loss of balance, or coordination problems
- Sudden severe headache with no known cause
These may be signs of a stroke, which is an uncommon side effect in patients who have never had a stroke or TIA.
- Fever with bleeding under the skin (tiny red pinpoint spots), unexplained extreme tiredness, confusion, or yellowing of skin/eyes — may indicate thrombotic thrombocytopenic purpura (TTP)
- Rash, itching, swollen face/lips/tongue, or difficulty breathing — may indicate a severe allergic reaction
- Blood in urine, rectal bleeding, black stools, or bleeding that cannot be stopped — signs of significant bleeding
Side Effects by Frequency
Common
- Bleeding from the stomach or intestines
- Bleeding from the catheter insertion site
- Nosebleeds (epistaxis)
- Skin rash
- Small red bruises on the skin (ecchymosis)
- Blood in the urine (haematuria)
- Bleeding under the skin or into a muscle causing swelling (haematoma)
- Low haemoglobin or red blood cell count (anaemia)
- Bruising
Uncommon
- Allergic reactions (rash, itching, swollen lips/tongue, or difficulty breathing)
- Spontaneous bleeding from the eye, rectum, gums, or into the abdomen around internal organs
- Post-operative bleeding
- Coughing up blood (haemoptysis)
- Blood in the stool
Rare
- Low platelet count (thrombocytopenia)
- Subcutaneous haematoma (bleeding under the skin causing swelling)
Understanding Your Bleeding Risk
The risk of bleeding with prasugrel must be weighed against the benefit of preventing cardiovascular events. In the TRITON-TIMI 38 trial, major bleeding occurred in approximately 2.4% of patients taking prasugrel compared to 1.8% taking clopidogrel. However, prasugrel significantly reduced the risk of heart attack (7.3% vs 9.5%), resulting in an overall net clinical benefit for most patient subgroups.
Certain factors increase your bleeding risk while on prasugrel: advanced age (75 years or older), low body weight (under 60 kg), concomitant use of other blood-thinning medications, recent surgery or trauma, and a history of gastrointestinal bleeding. If you are in any of these higher-risk categories, your doctor will have adjusted your dose or monitoring accordingly.
If you notice any unusual or prolonged bleeding, even if it seems minor (such as prolonged bleeding from a small cut, heavier-than-normal menstrual periods, or unexplained bruising), inform your doctor. Most bleeding events can be managed with local measures or temporary dose adjustments, but early reporting is important.
Reporting Side Effects
Reporting suspected side effects after a medicine has been authorised is important. It allows continued monitoring of the benefit-risk balance of the medicine. Healthcare professionals and patients are encouraged to report any suspected adverse reactions to their national pharmacovigilance authority (e.g., the MHRA in the UK, the FDA in the US, or the EMA in the EU).
How Should You Store Prasugrel Krka?
Proper storage of Prasugrel Krka ensures that the medicine remains effective and safe throughout its shelf life. Follow these storage guidelines carefully:
- Temperature: Store at no more than 30°C (86°F). Do not refrigerate or freeze.
- Packaging: Keep the tablets in the original blister packaging to protect them from moisture. Prasugrel is moisture-sensitive, and exposure to humidity may affect the stability of the active ingredient.
- Children: Keep this medicine out of the sight and reach of children. Accidental ingestion by a child can cause serious bleeding.
- Expiry date: Do not use Prasugrel Krka after the expiry date stated on the carton after "EXP." The expiry date refers to the last day of that month.
- Disposal: Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures help protect the environment.
What Does Prasugrel Krka Contain?
Active Substance
Each film-coated tablet contains 5 mg or 10 mg of prasugrel (as prasugrel hydrochloride). Prasugrel is a thienopyridine prodrug that is converted in the body to its active thiol metabolite, which irreversibly inhibits the P2Y12 platelet receptor.
Other Ingredients
Tablet core: Microcrystalline cellulose, macrogol 4000, poloxamer 188, fumaric acid (for pH adjustment), croscarmellose sodium, hydrophobic colloidal silica, mannitol, and magnesium stearate.
Film coating: Hypromellose, lactose monohydrate, titanium dioxide (E171), triacetin, yellow iron oxide (E172) (5 mg tablets only), and red iron oxide (E172) (10 mg tablets only).
Appearance and Pack Sizes
5 mg tablets: Pale brownish-yellow, oval, biconvex, film-coated tablets measuring 8.5 mm × 4.5 mm. Available in packs of 28, 30, and 84 tablets in blister strips.
10 mg tablets: Pink, oval, slightly biconvex, film-coated tablets measuring 10.5 mm × 5.5 mm. Available in packs of 28, 30, 84, and 90 tablets in blister strips.
Not all pack sizes may be marketed in all countries.
Marketing Authorisation Holder and Manufacturer
Marketing Authorisation Holder: KRKA, d.d., Novo mesto, Smarjeska cesta 6, 8501 Novo mesto, Slovenia.
Manufacturer: KRKA, d.d., Novo mesto, Smarjeska cesta 6, 8501 Novo mesto, Slovenia.
Prasugrel Krka is a generic medicine. Other brands of prasugrel available internationally include Prasugrel Viatris and the originator brand. All contain the same active substance and work in the same way.
Frequently Asked Questions About Prasugrel Krka
Prasugrel Krka is used to prevent blood clots in patients who have had a heart attack (myocardial infarction) or unstable angina and have been treated with percutaneous coronary intervention (PCI), such as coronary stent placement. It works by stopping platelets from clumping together, reducing the risk of another heart attack, stroke, or cardiovascular death. It is always taken together with aspirin as part of dual antiplatelet therapy (DAPT), typically for 12 months.
Both prasugrel and clopidogrel are P2Y12 receptor inhibitors used to prevent blood clots. However, prasugrel provides faster, more potent, and more consistent platelet inhibition than clopidogrel. In the TRITON-TIMI 38 trial, prasugrel reduced the risk of cardiovascular events by 19% compared to clopidogrel, but was associated with a slightly higher risk of major bleeding. Importantly, prasugrel is contraindicated in patients with prior stroke or TIA, while clopidogrel is not. Clopidogrel's effectiveness can also be reduced in patients who are "poor metabolizers" due to genetic variations in the CYP2C19 enzyme, a limitation that does not apply to prasugrel.
While there is no absolute prohibition on alcohol with prasugrel, excessive alcohol consumption can increase the risk of gastrointestinal bleeding and may interact with other medications you are taking for your heart condition. It is advisable to limit alcohol intake and discuss your drinking habits with your doctor. Moderate alcohol consumption (up to one standard drink per day for women and up to two for men) is generally considered acceptable, but always follow your doctor's specific advice.
The standard recommendation is to take Prasugrel Krka for 12 months after percutaneous coronary intervention (PCI) with stent placement. This duration is supported by the ESC and AHA/ACC guidelines. However, your doctor may shorten or extend this period based on your individual risk profile. Patients at very high bleeding risk may be considered for shorter DAPT (3-6 months), while those at high thrombotic risk may benefit from extended therapy beyond 12 months. Never stop taking prasugrel without consulting your doctor, as premature discontinuation significantly increases the risk of stent thrombosis.
Yes, bleeding is the most common side effect of Prasugrel Krka. This is expected because the medicine works by preventing platelets from forming clots. Most bleeding events are mild, such as nosebleeds, bruising, or minor bleeding from cuts that takes longer to stop. However, serious or life-threatening bleeding can occur in rare cases. Seek immediate medical attention if you experience uncontrollable bleeding, blood in your urine or stool, vomiting blood, or signs of stroke (sudden weakness, confusion, severe headache).
Inform your dentist that you are taking Prasugrel Krka before any dental procedure. For minor procedures (fillings, cleaning), prasugrel can usually be continued. For more invasive dental surgery (extractions, implants), your doctor may recommend stopping prasugrel 7 days before the procedure to allow platelet function to recover. However, this decision must be made in consultation with both your cardiologist and dentist, as stopping prasugrel carries the risk of stent thrombosis. Never stop taking prasugrel on your own without medical advice.
References
- Wiviott SD, Braunwald E, Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes (TRITON-TIMI 38). New England Journal of Medicine. 2007;357(20):2001-2015. doi:10.1056/NEJMoa0706482
- European Society of Cardiology (ESC). 2023 ESC Guidelines for the management of acute coronary syndromes. European Heart Journal. 2023;44(38):3720-3826.
- Levine GN, Bates ER, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy. Journal of the American College of Cardiology. 2016;68(10):1082-1115.
- European Medicines Agency (EMA). Prasugrel – Summary of Product Characteristics. Available at: ema.europa.eu
- National Institute for Health and Care Excellence (NICE). Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes. Technology appraisal guidance [TA317]. 2014.
- Valgimigli M, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease. European Heart Journal. 2018;39(3):213-260.
- World Health Organization (WHO). Model List of Essential Medicines – 23rd list, 2023. Geneva: WHO; 2023.
- Roe MT, Armstrong PW, et al. Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization. New England Journal of Medicine. 2012;367(14):1297-1309.
Medical Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, comprising board-certified physicians specialising in cardiology, clinical pharmacology, and internal medicine. Our content follows the GRADE evidence framework and is based exclusively on peer-reviewed research and international clinical guidelines.
All content is reviewed by specialist physicians with expertise in cardiovascular medicine and antiplatelet therapy. Our review process follows WHO, ESC, and AHA/ACC guidelines.
iMedic receives no commercial funding from pharmaceutical companies. All content is editorially independent with no conflicts of interest.
Evidence Level: This article is based on Level 1A evidence, including systematic reviews, meta-analyses, and landmark randomised controlled trials (TRITON-TIMI 38). Last reviewed: May 10, 2026.